KUALA LUMPUR, May 31 (Bernama) -- Hitachi Energy, the global technology and market leader in power grids, announced it has won an order from Deutsche Bahn to provide a 120 megawatt (MW) converter station which enables DB Energie to secure power supply for the Greater Berlin rail network.
According to a statement, the network serves a metropolitan population of around 3.5 million people and is the hub for multiple high-speed train services to cities throughout Germany and neighbouring countries. “We are delighted that Deutsche Bahn has selected Hitachi Energy as partner of choice to secure the 16.7 Hz power supply for their rail network,” said Niklas Persson, Managing Director of Hitachi Energy’s Grid Integration business. “This is an excellent example of how we collaborate together with customers and partners to accelerate the energy transition and advancing a sustainable energy future for all.” The Thyrow converter station, south of Berlin, will enable Deutsche Bahn to convert electricity from the public three-phase power distribution grid, which operates at a frequency of 50 hertz (Hz) to 16.7 Hz, and feed it into the rail power grid used to power trains and rail infrastructure. The order follows one awarded last year by Deutsche Bahn to Hitachi Energy for the 160 MW Delitz converter station in the greater Halle/Leipzig area, which will be one of the most powerful converter stations for rail power worldwide. The Hitachi Energy solution for the Thyrow converter station comprises three compact 40 MW static frequency converter modules, which use Hitachi Energy’s advanced power semiconductors to provide a steady and reliable power supply at maximum availability and with minimal electrical losses. The solution includes a 30-year service contract and a digitalisation package to provide Deutsche Bahn with condition-based and reactive maintenance and data insights into the system status of the converter station over the life cycle. -- BERNAMA
0 Comments
GUANGZHOU, China, May 30 (Bernama-BUSINESS WIRE) -- LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Number:e16102 Abstract Title:Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis. The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [¹]. Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [²]. Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs. In our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals. About Catumaxomab Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847). About LintonPharm LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com Reference 1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ 2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289. View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005174/en/ Contact Media Contacts: Mia He LintonPharm [email protected] Source : LintonPharm Co., Ltd. --BERNAMA GRADIANT, TECHNOLOGY LEADER IN SOLVING CRITICAL WATER PROBLEMS, RECEIVES COVETED GLOBAL WATER AWARDS30/5/2022 Gradiant named a “Water Technology Company of the Year” and Synauta, its recently acquired Machine Learning company, awarded “Breakthrough Technology Company of the Year”
BOSTON, May 30 (Bernama-BUSINESS WIRE) -- Gradiant, a global solutions provider and developer of cleantech water projects, today announced it has been recognized with distinction as “Water Technology Company of the Year'' and its recently acquired AI business, Synauta, was named “Breakthrough Technology Company of the Year” at the Global Water Intelligence (GWI) Global Water Awards in Madrid, Spain. Each year, these prestigious awards recognize the most important achievements in the global water industry. The winners are selected by the global water industry’s business leaders, investors, and technologists from the private and public sectors. Gradiant was recognized for its significant contributions to the field of water and digital technology, specifically for its: · Counterflow Reverse Osmosis (CFRO) technology that made membrane brine concentration a reality for industrial and municipal users around the world. For new SWRO facilities, membrane brine concentration has made recovery rates of >99% viable, radically shifting long-standing design paradigms · Global deployment of SmartOps digital platform which offers continuous optimization of systems with variable feedwaters – one of the biggest challenges for zero and minimum liquid discharge technologies. Industrial and municipal customers are increasingly adopting AI platforms for their water and wastewater operations to address challenges from sustainability and cost pressures, business continuity, regulatory compliance, and climate events. · Pipeline of disruptive innovations resulting in more than 250 patents and applications that allow the company to address a broad range of emerging end-use applications. GWI said at the time of award, “No other company has brought more solutions to the industrial sector’s difficult water treatment challenges in the last 10 years.” “It’s an honor to be recognized by our industry peers for our business growth, innovation, and technology adoption,” said Anurag Bajpayee, CEO of Gradiant. “Our expertise in digitizing and optimizing water has created new long-term value for our customers and competitive differentiation. We are grateful to our customers to trust Gradiant for solving their unique water challenges.” Synauta, which was recently acquired by Gradiant, was awarded for its commercial breakthroughs in global water technology. Synauta optimizes the performance of desalination plants through machine learning algorithms. Synauta’s “setpoints-as-a-service” offering revolutionized the practices of desalination and reuse plant operators. Expansion into new geographies and securing new industry partnerships validated the role that data and machine learning will serve to reduce the energy, chemicals, and carbon footprint in the future of water. About Gradiant Gradiant is a global solutions provider and developer of cleantech water projects. Gradiant’s end-to-end solutions and technology expertise enable sustainable and cost-effective treatment of the world's most important water challenges. With a full suite of differentiated and proprietary technologies, powered by the top minds in water, Gradiant serves its clients' mission-critical operations in the world's essential industries. Gradiant was founded at the Massachusetts Institute of Technology (MIT) and is uniquely positioned to address the world’s increasing challenges created by industrialization, population growth, and water stress. Today, with over 400 employees, Gradiant operates from its global headquarters in Boston, regional headquarters and global technology labs in Singapore, and offices across ten countries. For more information, please visit gradiant.com. About Synauta Synauta combines a deep understanding of desalination and machine learning artificial intelligence to treat more water with less energy and chemicals to reduce operating costs for our customers. The company’s proprietary algorithms determine optimal operating conditions and maintenance programs for water facilities of leading organizations around the world. More information at synauta.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005460/en/ Contact Corporate Felix Wang Gradiant, VP of Marketing [email protected] Media Consort Partners [email protected] Source : Gradiant --BERNAMA PARIS, May 26 (Bernama-BUSINESS WIRE) -- SFA, a World-Renowned Group, launches its Environmental Division: SFA enviro. Specialized in the design and manufacture of Wastewater Treatment Equipment since 1958, the group is mainly known for having revolutionized the sanitary equipment market.
New division, SFA enviro, the result of the SFA Group's International Growth Strategy. With more than 1,000 employees in 27 countries worldwide, the SFA Group has a portfolio of leading brands, including Europelec and Aquaturbo. The Group’s core business is closely linked to the Treatment of Municipal and Industrial Wastewater with a DNA focused on the Design and Manufacturing of Aeration Equipment. Thanks to 100 years of cumulative and international experience, SFA enviro supplies most of the equipment for Wastewater Treatment plants - from pre-treatment to sludge management - including process and treatment tanks and specific ancillary equipment used to settle, decant, aerate, and thicken Wastewater. Inventiveness is a priority for the SFA Group: Since the beginning, the Group has never stopped looking to the future and adapting to the ever-changing Market Place. Innovation, R&D, respect for the environment and customer service are at the heart of the Group's Core values. The SFA Group is committed to offering high performance with quality products, manufactured in Europe and the USA. Companies part of SFA enviro Division: Europelec (France), Aquasystems International N.V. (Belgium) and Aquaturbo Systems Inc (USA). R&D Department works in partnership with French and other higher education and research institutions. Much of the Equipment has been in service Worldwide for more than 30 to 35 years, with references in many Industrial Sectors such as Dairy Industry, Pulp and Paper, Mining, Food Processing, Meat Rendering, Oil and Gas, Pharmaceutical Industry, Sugar production, Livestock and Fish farming etc... Prestigious Customers: AQUAFIN, METITO, VEOLIA, SEVERN TRENT, SAUR, WATERLEAU, SUEZ, VINCI, NIJHUIS, BENTLEY, PANTAREIN, MAREL, NESTLÉ, ASIATEX, APP SINAR MAS, TOTAL ENERGIES, LACTALIS, SACROFINA, TEREOS, GRUMA, AGROSUPER, UNITED UTILITIES, THAMES WATER SEVERN TRENT,YORKSHIRE WATER, VALERO, SMURFITT KAPPA etc... The know-how of our skilled workers, some of whom have more than 30 years of experience, is perpetuated through recruitment programs and training of apprentices in the FABRICATION, MACHINING, WELDING, FITTING AND INSTALLLING PLUS COMMISSIONING. Our brands: Aerospeed®, Aerostream®, Aircomb®, Aquafenr, Aquadecant®, Aquaeromix®, Aquadisc®, Aquafloat®, Aquatube®, Aquaturbo®, Euromix®, Europelec®, Noemi®, Screwpeller®, Sofie® and TLF®. Learn more: www.sfa-enviro.com View source version on businesswire.com: https://www.businesswire.com/news/home/20220513005310/en/ Contact Contact: Louis-Serge Réal del Sarte, MarCom Director [email protected] +33(0)7-62-38-68-82 Source : SFA enviro --BERNAMA KUALA LUMPUR, May 26 (Bernama) -- The Malaysian Financial Planning Council (MFPC) signed a Memorandum of Agreement (MoA) today with MAHSA University, recognising the University as one of MFPC’s education providers.
As of May 2022, a total of 25 public and private universities in Malaysia are listed as MFPC education providers, enabling undergraduates of these universities to obtain an affiliate MFPC qualification and more importantly, be equipped with sufficient financial planning knowledge to practise effective financial planning in their own lives. Further, the qualification will enable them to pursue careers in the financial planning sector, thus enlarging the pool of qualified financial advisors, necessary to equip Malaysians with much-needed financial education and advice. MFPC’s RFP and Shariah RFP designations are approved qualifications for individuals embarking on careers in personal financial advisory. The designations are approved by Bank Negara Malaysia for the application of the Financial Adviser’s Licence (FAR) and by Securities Commission for the Capital Market Services Representative’s Licence (CMSRL). The RFP and Shariah RFP programmes are also accredited by the Finance Accreditation Agency (FAA), an agency set up by the regulators and that is responsible for certifying the standards and quality of professional learning and development in the financial services industry. At the event, MFPC President, Vincent Kwo, stated, “One of the key learnings of the Covid-19 pandemic for all segments of Malaysian society is the importance of financial resilience. When economies were muted and businesses were forced to be closed, many had poor financial buffers and did not have what we term as ‘emergency savings’. As the pandemic taught us, longer and sustainable emergency savings is required both for individuals and businesses, debunking conventional wisdom of the 6 months’ of emergency savings requirement”. Assoc. Prof. Alla Kesava Rao of MAHSA said, “MAHSA University is always aligned to the Malaysian government’s initiatives and is committed to create competent financial professionals through this agreement.” Ever since its inception in 2004, MFPC has worked towards developing the financial planning profession through our professional education programmes and introducing several initiatives and projects to raise the financial literacy of Malaysians from all walks of life. The Council’s free financial literacy programme, My Money and Me, is among our flagship initiatives to this end. The negative impact of the Covid-19 pandemic on the finances of Malaysians is clear as seen by the number of individuals who have had to tap into their retirement funds just to survive. Effective Financial Planning education is obviously an important factor in transforming the financial well-being of Malaysians, empowering them to withstand financial shocks. Malaysian Financial Planning Council (MFPC) The Malaysian Financial Planning Council (MFPC) was set up in in 2004 with the objective of promoting nationwide development and enhancement of the financial planning profession. Its mission now includes raising the financial literacy of all Malaysians by being at the forefront of raising Malaysians’ financial literacy. This reflects our corporate social responsibility to the rakyat and the nation and underscores our initiatives to meet the crucial need to elevate financial knowledge among Malaysians, many of whom are struggling to meet everyday living needs. SOURCE: Malaysian Financial Planning Council (MFPC) FOR MORE INFORMATION PLEASE CONTACT: Name: Syed Mohd Khalil External Relations, Research and Publication Malaysian Financial Planning Council Tel: +603 62035899 Email: [email protected] --BERNAMA KUALA LUMPUR, May 24 (Bernama) -- Crocus Technology Inc, the leading supplier of disruptive TMR (Tunnel Magneto-Resistance) XtremeSense® sensors, has announced the CT45x family of contactless isolated current sensors to enable high precision and high current measurements in a more simplified solution.
“With the introduction of the CT45x family of contactless current sense products, we now have a complete portfolio of products for our customers from small currents to larger currents,” said President and CEO of Crocus Technology, Zack Deiri. “This product based on Crocus’ cutting-edge TMR technology is the most exciting for us as the benefits of our XtremeSense TMR are addressing the needs of higher current applications that can’t be met with existing solutions without compromises.” According to a statement, unlike existing solutions, the CT45x allows manufacturers to eliminate costly shields, concentrators or cores. The CT452 and CT453 offers contactless 0.7 per cent accuracy, 1 MHz bandwidth, and better than -50 dB immunity to external magnetic fields without additional mechanical components. This combination of performance and accuracy enables customers to reduce their overall product size and weight which enables them to replace large and costly current sense modules with a small and simple solution. The CT45x products are based on XtremeSense TMR technology that delivers the future with a high signal-to-noise ratio (SNR) contactless approach which can scale with the system requirements, high bandwidth and fast response time, common-model field rejection, combined with high accuracy measurements over temperature. The CT45x offers groundbreaking noise performance, as low as 0.55 mVRMS, to enable applications to sense small current levels and small changes or variations in current through a busbar. This performance is almost 10 times better than existing Hall Effect solutions. This results in a SNR (signal-to-noise ratio) as high as 77 dB for the CT45x measurement which allows the system to process higher resolution data with higher accuracy. More details at http://www.crocus-technology.com. -- BERNAMA KUALA LUMPUR, May 24 (Bernama) -- Hitachi Ltd has announced the launch of Lumada Inspection Insights, its end-to-end portfolio of digital solutions for the inspection, monitoring, and optimisation of critical assets.
Pioneered by Hitachi Energy and Hitachi Vantara, Lumada Inspection Insights enables customers to automate asset inspection, support sustainability goals, improve physical security, and reduce risks and impacts related to storms or fires by using powerful artificial intelligence (AI) to analyse photographs and video, including LiDAR, thermal and satellite imagery. According to a statement, the launch of the new portfolio is fully aligned with Hitachi’s Mid-term Management Plan 2024 announced last month by Keiji Kojima, President & CEO, Hitachi Ltd. In the Plan, Hitachi has set out its growth strategy and commitment to strengthening its digital and green portfolio, which is centred on the Lumada ecosystem. Central to Hitachi’s commitment to social innovation, the Lumada ecosystem is accelerating the journey towards sustainable society through the data-driven cycle of value co-creation with customers. The company is also focused on growing its IT/OT/Products business through constant portfolio transformation. The new Lumada Inspection Insights portfolio addresses various root causes of failures and forced shutdowns by deploying AI and machine learning (ML) to analyse a wide spectrum of image types, assets and risks. Predictive analytics assesses the risks to operations or environment, and organisations can streamline remediation before outages occur. Available as a comprehensive solution or standalone, the portfolio’s four core applications are Hitachi Image Based Inspections, Hitachi Intelligent Infrastructure Monitoring, Hitachi Vegetation Manager, and Hitachi Map, representing the company’s latest advancements in its growing Data Operations (DataOps) and Industrial IoT offerings. Massimo Danieli, Managing Director of Hitachi Energy’s Grid Automation business said: “In collaboration with Hitachi Vantara, we are delighted to launch the Lumada Inspection Insights portfolio, which gives industrial organisations the tools they need to get the right information to the right teams when they need it most. The result is improved reliability, safety, and sustainability.” Lumada Inspection Insights features comprehensive, microservices-based capabilities that allow visibility of assets and factors such as current state, asset health, and encroachment, in a “single pane of glass” actionable view, from a variety of sources. With these unified insights, organisations can improve safety, reliability, and agility. Hitachi is exhibiting Lumada Inspection Insights at DISTRIBUTECH INTERNATIONAL 2022, which is held from May 23 at Dallas, Texas, United States. -- BERNAMA TOKYO, May 24 (Bernama-BUSINESS WIRE) -- bitbank, inc. (HQ: Tokyo Japan CEO: Noriyuki Hirosue) and Sumitomo Mitsui Trust Holdings, Inc. (HQ: Tokyo Japan, Director, President: Toru Takakura) have signed a memorandum of understanding with the purpose to establish “Japan Digital Asset Trust Preparatory Company, inc. *1 “JADAT”” which will be a preparatory company for the purpose of establishing a trust company specializing in digital assets*2. In the MOU, both parties agree to study the possibility of SuMi TRUST Holdings to invest in JADAT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005408/en/ JADAT will get the know-how of digital asset storage management system with Japan's most advanced and highest security level of bitbank and the know-how of trust business of SuMi TRUST Holdings - a specialized trust bank group. *1 After the registration by the related authorities based on the Trust Business Act, it is expected to change its business name to Japan Digital Asset Trust, inc.. *2 Crypto assets, security tokens on public blockchain, stablecoins and NFTs. About the new company Name: Japan Digital Asset Trust Preparatory Company, inc. CEO: Noriyuki Hirosue Business content: Digital asset custody business Website: http://jadat.com/en About bitbank, inc. [Introduction] bitbank operates the Japanese crypto asset exchange “bitbank” - which has monthly domestic trade volume of 731.7 billion JPY, domestic trade volume share of 33.7% (as in April 2021) and deposits of clients of more than 300 billion JPY - is rapidly expanding its business scale. In order to expand the domestic crypto asset market, it is necessary that more institutional investors enter the market. With our strengths - crypto asset storage technology, liquidity of spot trades, strong security - we will contribute to the further expansion of the crypto asset market, through digital asset trust business with JADAT. [Company name] bitbank, inc. [URL] https://bitbank.cc/about/corporate [CEO] Noriyuki Hirosue [Address] 141-0031 7F, KDX Nishigotanda Building, 7-20-9 Nishigotanda, Shinagawa, Tokyo, Japan [Date of establishment] May 7th, 2014 [Initial capital] 8,647.21 million JPY (Incl. capital reserves) [Business description] Crypto asset (cryptocurrency) related services Crypto asset exchange operator, Registration No. 00004, issued by the Director of the Kanto Local Finance Bureau [Memberships] Japan Virtual and Crypto assets Exchange Association (JVCEA) Japan Crypto Asset Business Association (JCBA) Blockchain Collaborative Consortium (BCCC) View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005408/en/ Contact bitbank, inc. Midori Abe +81-50-1751-8600 [email protected] Source : bitbank, inc. http://mrem.bernama.com/viewsm.php?idm=43232 Investigators Report Positive Findings From Feasibility Study of CCM in Heart Failure With Preserved Ejection Fraction at the European Society of Cardiology Heart Failure 2022 Congress MADRID and MARLTON, N.J., May 24 (Bernama-GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a late-breaking presentation of results from the CCM-HFpEF Piloty Study, which is the largest clinical trial to date studying the effects of the company’s proprietary CCM® therapy to treat HF with preserved ejection fraction (HFpEF). The results presented — including a substantial 18 point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ) quality of life score — indicate that, for patients with heart failure and left ventricular ejection fraction (LVEF) ≥50%, CCM therapy not only offered meaningful improvement in quality of life but also substantially decreased hospitalizations versus the patient’s experience prior to the Optimizer® implant. The results were presented at the European Society of Cardiology’s Heart Failure 2022 Congress. Patients with HFpEF suffer from debilitating symptoms and have very few therapeutic options. This patient population is a similar size as the one with reduced ejection fraction and has been shown to have similar struggles with quality of life, hospitalizations, and mortality. Cecilia Linde, MD, Professor and Consultant in Cardiology at the Heart and Vascular Theme of Karolinska University Hospital and the Karolinska Institute in Stockholm, Sweden, who was the co-principal investigator for this investigation, said, “The CCM-HFpEF Pilot Study was conducted to explore the hypothesis that CCM therapy might benefit patients with HFpEF. Our hypothesis was based on evidence of greater benefits in CCM HFrEF studies in those with higher LVEF range and from case reports of HFpEF patients. In our CCM-HFpEF-Pilot Study, we found significant benefits from CCM therapy in patients with preserved LVEF, supporting prior findings. I look forward to following the progress of the recently begun pivotal AIM HIGHer trial to continue this journey further.” Dr. Ishu Rao, Medical Director for Impulse Dynamics, welcomed these results because they confirm the potential for positive results in the company’s recently initiated AIM HIGHer trial. “We are also excited to announce that enrollment is well underway for this landmark IDE-approved, multicenter, randomized, and blinded pivotal trial designed not only to confirm Dr. Linde’s groundbreaking work presented today but to go further yet by providing the first long term morbidity and mortality results for a modern Optimizer CCM device. While Dr. Linde specifically studied patients with EFs ≥50%, in AIM HIGHer, we are examining the efficacy of CCM therapy in 1,500 patients with EFs between 40% and 60%. This represents a large cohort of patients who currently have minimal treatment options and are clamoring for help. If AIM HIGHer's results are consistent with Dr. Linde’s findings, we may finally begin to close the significant gap in care that exists for millions of patients afflicted with HF and higher EF.” HF affects more than 64 million people worldwide and leads to dramatic declines in a patient’s quality of life. Patients are often classified by a measure of cardiac function known as the ejection fraction (EF), which describes the percentage of blood pumped out of the left ventricle with each heartbeat. CCM therapy is currently indicated in Europe for patients that have an EF below 50% and has been proven to reduce hospitalizations. However, HF patients with higher EF have had few therapeutic options thus far to alleviate their symptoms and treat their disease. The purpose of the AIM HIGHer trial — the largest randomized, sham-controlled, device-based interventional heart failure trial — is to further assess the potential of CCM to improve performance and reduce cardiovascular morbidity and mortality for these patients. CCM therapy for HFpEF has already received the FDA’s breakthrough device designation. The Breakthrough Devices Program is a voluntary program for certain medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review while preserving the statutory standards consistent with the Agency's mission to protect and promote public health. The Optimizer Smart Mini delivers CCM therapy which consists of precisely timed electrical pulses sent to the heart. These signals are designed to improve the heart’s ability to function properly, allowing more oxygen-rich blood to be pushed out through the body. About Impulse Dynamics Impulse Dynamics, based in Marlton, NJ, is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company has pioneered CCM® therapy, which is delivered by the company’s Optimizer® Smart Mini, an FDA-approved treatment verified to improve the quality of life for certain heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook. Forward-looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: potential benefits of CCM therapy and the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Smart Mini and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the Company’s future research and development costs, capital requirements and the Company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the Company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer Smart and Optimizer Smart Mini systems or any future products the Company may seek to commercialize; competitive companies and technologies in the industry; the Company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the Company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the Company’s ability to expand, manage and maintain its direct sales and marketing organization; the Company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the Company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The Company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. ### Rex Richmond, Director (Media Relations) Impulse Dynamics 856-642-9933 [email protected] Harriss Currie, CFO (Investor Relations) Impulse Dynamics 856-642-9933 [email protected] Ian Segal, Manager (Public Relations) Impulse Dynamics 856-642-9933 [email protected] SOURCE : Impulse Dynamics PUTRAJAYA, May 24 (Bernama) -- The 200 participants of the Perdana Leadership Foundation SME Leaders Programme 2022 “Knowledge Exchange for Entrepreneurship Excellence” taking place on 25th May at Perdana Leadership Foundation in Putrajaya will get the chance to dialogue with one of the country’s eminent business leaders and Chairman of the Foundation’s Board of Trustees, Tan Sri Azman Hashim, at an hour-long live Special Session. Tan Sri Azman Hashim, who charted an illustrious career as a Chartered Accountant turned banker, will share his experience as an entrepreneur and business owner.
“Most of the big businesses of today started as a micro and small enterprise. What enabled these businesses to grow was a combination of factors but leadership plays a big role in determining success or failure. This programme by PLF for MSME leaders is timely because there are many that need direction and support to recover from the lockdowns. The dialogues and discussions featured in the event will hopefully prompt new ideas, open up new possibilities, and lead to new business collaborations that can benefit entrepreneurs,” said Tan Sri Azman. YABhg Tun Dr Mahathir Mohamad, Former Prime Minister of Malaysia & Honorary President of Perdana Leadership Foundation, will deliver the closing remarks via a video message at the conclusion of the programme. The event will be officiated by Dato’ Suriani binti Dato' Ahmad, Secretary-General, Ministry of Entrepreneur Development and Cooperatives. The Special Dialogue is one of many sessions that will take place at this event for micro, small, and medium business leaders. The one-day in-person programme will feature speeches by CEOs of MSMEs, breakout sessions facilitated by business leaders, and info talks, all designed to facilitate discussion and idea-sharing by entrepreneurs. “With many micro, small, and medium businesses struggling to recover from the pandemic, this programme is a way to energise MSME leaders and connect them with their peers from diverse sectors. The programme is also designed to highlight best practices and painful lessons learned from established and new enterprises, with the understanding that the best learning comes from experience, whether it be one’s own or another’s,” said Tan Sri Nik Mohamed Nik Yaacob, Executive Director, Perdana Leadership Foundation. Speakers include: Ms See Wai Hun, CEO of Juristech; Puan Saliza Abdullah, CEO of BG Capital Holdings; Dr Hanafiah Yussof, CEO of Robopreneur; Mr Aizat Rahim, MD of Dropee; Mr Azlan Shah, Founder and CEO, Kelava, and others. There will also be short talks by Mr Rizal Nainy, CEO, SME Corporation Malaysia, and Mr Mohd Redzuan Affandi bin Abdul Rahim, Director, Digital Adoption Department, Digital Economy Ecosystem Division, of MDeC. The PLF SME Leaders Programme is organised by Perdana Leadership Foundation. Thanks to the generous sponsorship of Affin Bank (Gold Sponsor), PNS and AmBank (Bronze Sponsors), admission to the event is entirely free. More information is at www.perdanasmeleaders.com. Note: This is a face to face event. All participants need to wear a face mask for entry and during sessions, must be symptom-free, and must not be under any quarantine / Home Surveillance Order. Please click here for PROGRAMME ABOUT PERDANA LEADERSHIP FOUNDATION www.perdana.org.my The Foundation is a non-profit organisation established in 2003 to document, disseminate, research, and archive materials related to the past Prime Ministers of Malaysia, and nation-building. The Foundation intends to become the premier institution for the study of Malaysia’s Prime Ministers and the central resource centre for research into national stewardship as well as a platform for reflection, debate, and discussion with distinguished figures in Malaysian leadership. Our Honorary President is the fourth and seventh Prime Minister of Malaysia, YABhg Tun Dr Mahathir Mohamad. To date, we have digitised more than 500k materials, half of which are available through our website www.perdana.org.my. SOURCE: PERDANA LEADERSHIP FOUNDATION FOR MORE INFORMATION PLEASE CONTACT: Name: Nurul Humaira Kamarulzaman Designation: Executive, Events and Publications Tel: 03 - 88858960 Email: [email protected], [email protected] Name: Mohammad Faridzuan Abd Rahman Designation: Executive, Communications and Publications Tel: 03 - 88858953 Email: [email protected], [email protected] --BERNAMA |
Archives
April 2023
Categories |